Screener
Madrigal Pharmaceuticals, Inc. MDGL Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 9:06 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050845
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Proceeds from exercise of common stock options | 5,441 | 10,381 |
| Net cash provided by financing activities | 5,441 | 10,381 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 1,377 | — |
| Net increase in cash, cash equivalents, and restricted cash | 89,098 | 86,174 |
| Cash, cash equivalents, and restricted cash at beginning of period | 203,783 | 105,019 |
| Cash, cash equivalents, and restricted cash at end of period | $292,881 | $191,193 |
| Supplemental disclosure of cash flow information: | ||
| Obtaining an operating lease right-of-use asset in exchange for an operating lease liability | $1,692 | $3,982 |
Item 1. Financial Statements (Unaudited):
FAQ
- What is Madrigal Pharmaceuticals, Inc.'s net change in cash?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported net change in cash of $60.69M in Q2 2026.
- How has Madrigal Pharmaceuticals, Inc.'s net change in cash changed year-over-year?
- Madrigal Pharmaceuticals, Inc.'s net change in cash increased by 2282.9% year-over-year, from $2.55M to $60.69M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about Madrigal Pharmaceuticals, Inc.'s net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude